Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is still an incurable malignancy of plasma cells. Proteasome inhibitors (PIs) work as the backbone agent and have greatly improved the outcome in majority of newly diagnosed patients with myeloma. However, drug resistance remains the major obstacle causing treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhen, Wei, Xiaojing, Liu, Lanting, Sun, Hao, Fang, Teng, Wang, Lu, Li, Ying, Sui, Weiwei, Wang, Kefei, He, Yi, Zhao, Yaozhong, Huang, Wenyang, An, Gang, Meng, Fancui, Huang, Changjiang, Yu, Tengteng, Anderson, Kenneth C., Cheng, Tao, Qiu, Lugui, Hao, Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958548/
https://www.ncbi.nlm.nih.gov/pubmed/35344764
http://dx.doi.org/10.1016/j.ebiom.2022.103950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958548/
https://www.ncbi.nlm.nih.gov/pubmed/35344764
http://dx.doi.org/10.1016/j.ebiom.2022.103950

Ejemplares similares